Proposed Acquisition of ResApp Health by Pfizer Australia Holdings Pty Limited, a wholly-owned subsidiary of Pfizer Inc, for $0.208 cash per share by scheme of arrangement.
Your Vote is Important
Your Directors unanimously recommend that you vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of ResApp Health Shareholders.
The Independent Expert has concluded that the Scheme is in your best interests, in the absence of a superior proposal.
Scheme Meeting
The Scheme Meeting is scheduled to take place at 2:00pm (AEST) on Wednesday, 7 September 2022 and will be held at the the offices of DLA Piper Australia, Level 22 No 1 Martin Place, Sydney and virtually via an online platform. To attend the Scheme Meeting virtually, please pre-register in advance for the virtual meeting here: https://us02web.zoom.us/webinar/register/WN_pvBR0ih1TKCkkQjgjNNGNg
Due to the ongoing COVID-19 pandemic, in the interests of the health and safety of ResApp Shareholders and staff, and uncertainty and disruption associated with Government restrictions on travel and large gatherings, the Scheme Meeting will be held as a hybrid meeting which can be attended virtually or in person. ResApp encourages ResApp Shareholders and their proxies, attorneys and corporate representatives to participate in the Scheme Meeting virtually.
All registered ResApp Shareholders at 7:00pm (AEST) on Monday, 5 September 2022 will be eligible to vote at the Scheme Meeting. Further information on how to participate in and vote at the Scheme Meeting is set out in the Scheme Booklet.